On June 11, METiS Pharmaceuticals-P (07666.HK) fell 5.26% in regular trading, trading at 11.55 HKD/share, with trading volume of approximately 19.01 million HKD. The stock has been in sustained retreat since surging 173% on its May 13 listing debut.

On the news front, the company's over-allotment option was fully exercised, involving 30,184,000 H shares issued at the IPO price of 10.50 HKD per share. These shares officially commenced trading on June 10, directly increasing market supply and intensifying selling pressure. Meanwhile, the price stabilization period ended on June 7, meaning the mechanism previously supporting the share price has formally withdrawn. Combined with the absence of lock-up periods for certain international placement shares, profit-taking pressure continues to weigh heavily on the stock, which has now fallen below its first-day closing level with significant retracement from its post-IPO high.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)